合生元
代谢综合征
肠道菌群
肠道微生物群
微生物群
疾病
调节器
人口
生物
生物信息学
失调
医学
免疫学
肥胖
内科学
益生菌
内分泌学
遗传学
环境卫生
细菌
基因
作者
Ricardo Araújo,Marta Borges‐Canha,Pedro Pimentel‐Nunes
出处
期刊:Nutrients
[MDPI AG]
日期:2022-10-25
卷期号:14 (21): 4490-4490
被引量:10
摘要
Metabolic syndrome (MS) comprises a vast range of metabolic dysfunctions, which can be associated to cardiovascular disease risk factors. MS is reaching pandemic levels worldwide and it currently affects around 25% in the adult population of developed countries. The definition states for the diagnosis of MS may be clear, but it is also relevant to interpret the patient data and realize whether similar criteria were used by different clinicians. The different criteria explain, at least in part, the controversies on the theme. Several studies are presently focusing on the microbiota changes according to the components of MS. It is widely accepted that the gut microbiota is a regulator of metabolic homeostasis, being the gut microbiome in MS described as dysbiotic and certain taxonomic groups associated to metabolic changes. Probiotics, and more recently synbiotics, arise as promising therapeutic alternatives that can mitigate some metabolic disturbances, namely by correcting the microbiome and bringing homeostasis to the gut. The most recent studies were revised and the promising results and perspectives revealed in this review.
科研通智能强力驱动
Strongly Powered by AbleSci AI